{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06235905",
            "orgStudyIdInfo": {
                "id": "NAV-17A-008"
            },
            "secondaryIdInfos": [
                {
                    "id": "SPN-820",
                    "type": "OTHER",
                    "domain": "Supernus Pharmaceuticals"
                }
            ],
            "organization": {
                "fullName": "Navitor Pharmaceuticals, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Open-Label of SPN-820 in Adults With Major Depressive Disorder",
            "officialTitle": "An Open-Label, Single-Group Study to Evaluate the Efficacy and Safety of SPN-820 in Adults With Major Depressive Disorder",
            "therapeuticArea": [
                "Other"
            ],
            "study": "open-label-of-spn-in-adults-with-major-depressive-disorder"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-02-15",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-10-15",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-10-15",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-01-23",
            "studyFirstSubmitQcDate": "2024-01-23",
            "studyFirstPostDateStruct": {
                "date": "2024-02-01",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-06",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-07",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Navitor Pharmaceuticals, Inc.",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Supernus Pharmaceuticals, Inc.",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study will evaluate the efficacy and safety of SPN-820 in Adults With Major Depressive Disorder (MDD)",
            "detailedDescription": "This is an open-label, single-group study of adjunctive SPN-820 in adults with MDD"
        },
        "conditionsModule": {
            "conditions": [
                "Major Depressive Disorder"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "Open-label",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 50,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "SPN-820 6 x 400 mg capsules",
                    "type": "OTHER",
                    "interventionNames": [
                        "Drug: NV-5138"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "NV-5138",
                    "description": "NV-5138 is a novel , orally bioavailable, activator of mTORC1",
                    "armGroupLabels": [
                        "SPN-820 6 x 400 mg capsules"
                    ],
                    "otherNames": [
                        "SPN-820"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Evaluation of the efficacy of SPN-820 administered once every 3 days as measured by the Hamilton Depression Rating Scale-6 Items",
                    "description": "Change from baseline to each time point in the Hamilton Depression Rating Scale-6 Items (HAM-D6).\n\nThe HAM-D6 scale consists of 6 items: five of them (Depressed Mood, Self-esteem and Guilt, Social Life Activities/Interests, General Psychomotor Retardation, and Psychic Anxiety) are scored on a scale of 0 to 4, and one item (Tiredness and Pains) is scored on a scale 0-2. The total score is the sum of the 6 items ranging from 0 to 22, higher scores indicate severe depression, and lower scores are better outcomes.",
                    "timeFrame": "10 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Evaluation of the efficacy as measured by the Montgomery-\u00c5sberg Depression Rating Scale (MADRS) score",
                    "description": "Change from baseline to each time point in the Montgomery-\u00c5sberg Depression Rating Scale (MADRS) total score.\n\nMADRS is a 10-item scale: (Reported sadness, Apparent sadness, Inner tension, Reduced sleep, Reduced appetite, Concentration difficulties, Lassitude, Inability to feel, Pessimist thoughts, and Suicidal thoughts) where each item is scored from 0 to 6. The total score is the sum of the 10 items ranging from 0 to 60 where higher scores indicate more severe depression and lower scores, better outcomes.",
                    "timeFrame": "10 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female subject, aged 18 to 65 years (inclusive) at screening.\n* Diagnosis of MDD according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) for either recurrent or single episode MDD without psychotic features that is confirmed by the Mini International Neuropsychiatric Interview (MINI) at screening.\n* MADRS total score of \u226522 for the current major depressive episode (MDE) at screening and baseline (day 1) before SM administration.\n* CGI-S score of \u22654 (moderately ill or worse) at screening and baseline (day 1) before SM administration.\n* Stable, therapeutic dose of one of the following protocol-defined ADTs for the current MDE for \u22654 weeks prior to screening: citalopram, escitalopram, paroxetine, fluoxetine, sertraline, duloxetine, venlafaxine (immediate release or extended release), desvenlafaxine, vilazodone, levomilnacipran, vortioxetine, bupropion, or dextromethorphan/bupropion.\n* Stable therapeutic dose of the approved ADT throughout the study.\n\nExclusion Criteria:\n\n* MADRS total score improvement of \u226525% from the highest to the lowest score from screening to baseline.\n* Clinically significant abnormal laboratory profiles, vital sign measurements, or ECGs prior to baseline.\n* History of psychotic disorder, including but not limited to schizophrenia, MDD with psychotic features, or bipolar I/II disorder with and without psychotic features.\n* Diagnosis within the last 12 months before screening or current diagnosis of PTSD, OCD, panic disorder, acute stress disorder, or has a history of intellectual disability, autism, or cluster A or B personality disorder.\n* Suicidal behavior or suicidal ideation of type 4 or type 5 based on the C-SSRS in the 2 years before screening; a history of suicide attempt in the last 6 months; or more than 2 lifetime suicide attempts.\n* History of substance use disorder within 6 months prior to screening or is currently using or has a positive result (urine drug screen) at screening or baseline for drugs of abuse.\n* History of alcohol use disorder within 6 months prior to screening.\n* In the investigator's opinion, is unlikely to comply with the protocol or is unsuitable for any other reason.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Gianpiera Ceresoli-Borroni, PhD",
                    "role": "CONTACT",
                    "phone": "3018382521",
                    "email": "gceresoliborroni@supernus.com"
                }
            ],
            "locations": [
                {
                    "facility": "Muhammad Saleem Ismail",
                    "status": "RECRUITING",
                    "city": "Rochester",
                    "state": "New York",
                    "zip": "14618",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 43.15478,
                        "lon": -77.61556
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003866",
                    "term": "Depressive Disorder"
                },
                {
                    "id": "D000003863",
                    "term": "Depression"
                },
                {
                    "id": "D000003865",
                    "term": "Depressive Disorder, Major"
                }
            ],
            "ancestors": [
                {
                    "id": "D000019964",
                    "term": "Mood Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                },
                {
                    "id": "D000001526",
                    "term": "Behavioral Symptoms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7058",
                    "name": "Depression",
                    "asFound": "Depressive Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7061",
                    "name": "Depressive Disorder",
                    "asFound": "Depressive Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7060",
                    "name": "Depressive Disorder, Major",
                    "asFound": "Major Depressive Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21835",
                    "name": "Mood Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4818",
                    "name": "Behavioral Symptoms",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}